Vir Biotechnology, Inc. (VIR) - Long-Term Debt to Capital

Vir Biotechnology, Inc. (VIR) develops advanced antibodies to combat infections, leveraging robust scientific potential and alliances with global industry leaders. The price history confirms a commitment to ESG principles and the reduction of harmful emissions during production. The current metric stands at 0.10. The business currently lacks pricing power due to the absence of a mass-market commercial product following the decline in demand for coronavirus treatments.

This indicator calculates the share of long-term loans (over one year) within the equity structure, determining the business's dependence on external debt financing. Analyzing the ratio of long-term liabilities to equity is critically important for Vir Biotechnology, Inc. (VIR), as declining revenues from pandemic-related contracts necessitate a balance between debt load and the resources required to launch new products.